Technical Analysis for SYBX - Synlogic, Inc.
|Grade||Last Price||% Change||Price Change|
SYBX closed up 1.83 percent on Friday, January 18, 2019, on 43 percent of normal volume. The price action carved out a bullish hammer (or hammer-like) candlestick pattern. That may indicate an upside reversal. Look for price to trade above the high of the hammer for confirmation.
|Weak or Absent||Down||Down||Down|
|See historical SYBX trend table...|
|Date||Alert Name||Type||% Chg|
|Jan 18||Hammer Candlestick||Bullish||0.00%|
|Jan 18||Narrow Range Bar||Range Contraction||0.00%|
|Jan 18||Wide Bands||Range Expansion||0.00%|
|Jan 17||Fell Below 20 DMA||Bearish||1.83%|
|Jan 17||MACD Bearish Signal Line Cross||Bearish||1.83%|
|Jan 17||Wide Bands||Range Expansion||1.83%|
|Jan 16||Crossed Above 20 DMA||Bullish||-2.69%|
|Jan 16||Wide Bands||Range Expansion||-2.69%|
|Jan 15||20 DMA Resistance||Bearish||0.42%|
|Jan 15||MACD Bearish Centerline Cross||Bearish||0.42%|
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicatorsBasic chart:
Synlogic, Inc., formerly Mirna Therapeutics, Inc., is engaged in the development of a novel class of living treatments, Synthetic Biotic medicines. The Company uses its proprietary Synthetic Biotic development platform. Its pipeline includes Synthetic Biotic medicines for the treatment of rare genetic diseases, such as Urea Cycle Disorder (UCD) and Phenylketonuria (PKU). It is also focused on Synthetic Biotic medicines to address other conditions, including inflammatory bowel disease , cancer and metabolic conditions, such as diabetes and obesity. The Company’s synthetic biotic medicines leverages the tools and principles of synthetic biology to genetically reengineer probiotic microbes to perform or deliver critical functions missing or damaged due to disease. The Company’s pipeline includes synthetic biotic medicines for the treatment of inborn errors of metabolism (IEM). It is developing SYNB1020 for the treatment of UCD and HE. It is developing SYNB1618 for the treatment of PKU.
|Indicator||Bull Case||Neutral / Hold||Bear Case|
|Oversold / Overbought|
|Summary:||Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.|
See more SYBX news...
|52 Week High||14.59|
|52 Week Low||5.75|
|200-Day Moving Average||9.8844|
|50-Day Moving Average||7.8364|
|20-Day Moving Average||7.426|
|10-Day Moving Average||7.762|
|Average True Range||0.6568|
|Chandelier Exit (Long, 3 ATRs )||7.0296|
|Chandelier Exit (Short, 3 ATRs )||7.7204|
|Upper Bollinger Band||8.7499|
|Lower Bollinger Band||6.1021|
|Percent B (%b)||0.43|
|MACD Signal Line||-0.0757|
|Market Cap||117.88 Million|
|Num Shares||16.3 Million|
|Price-to-Earnings (P/E) Ratio||-0.78|
|Pivot Point Level||Traditional / Classic||Fibonacci||Demark||Woodie||Camarilla|
|Resistance 4 (R4)||7.72|
|Resistance 3 (R3)||7.67||7.47||7.64|
|Resistance 2 (R2)||7.47||7.34||7.49||7.61|
|Resistance 1 (R1)||7.35||7.27||7.41||7.40||7.59|
|Support 1 (S1)||7.03||7.02||7.09||7.08||6.89|
|Support 2 (S2)||6.83||6.95||6.85||6.87|
|Support 3 (S3)||6.71||6.83||6.84|
|Support 4 (S4)||6.76|